Reinforcing its Upper Echelon: Dxcover Bolsters Leadership with Elite Scientific Consultants and Board Members of Global Repute
Dxcover, a pioneering company in oncology diagnostics, has announced significant additions to its Scientific Advisory Board (SAB) and Board of Directors. These appointments bring a wealth of expertise in neuro-oncology, gynaecological oncology, clinical trial methodology, and translational diagnostic research.
New Members of the Scientific Advisory Board
- Professor Katy Peters, MD PhD, Professor of Neurology and Neurosurgery at Duke University Medical Center, joins the SAB as an expert in neuro-oncology and clinical trial design. With deep knowledge of brain cancer care pathways and translational research, she will play a crucial role in bringing diagnostic innovations to clinical practice.
- Professor Emma Crosbie, MBChB(Hons) PhD MRCOG, Professor of Gynaecological Oncology at The University of Manchester and NIHR Research Professor, is renowned for her clinical and research expertise in early detection and prevention of endometrial and ovarian cancers. Her work in biomarker research and clinical trials will undoubtedly bolster Dxcover's efforts in oncology diagnostics development and clinical translation.
Other existing members of the SAB include Dr. Luke Pike MD DPhil, specialising in CNS malignancies, and Professor Paul Brennan MB BChir FRCS(Ed) PhD, a globally recognised expert in brain cancer diagnostics. Additionally, Professor William E. Fisher MD FACS, a leading authority in pancreatic surgery and oncology, has been appointed to the SAB.
Enhancing Leadership with Strategic Expertise
While the exact identities and specific expertise of the new members of the Board of Directors were not disclosed, the announcement highlights that Dxcover is strengthening its leadership with strategic expertise spanning clinical statistics, artificial intelligence, and commercial diagnostics.
Guiding Dxcover's Commercial Strategy
Stacy Chick, an experienced global commercial life sciences executive, has been advising Dxcover since 2021. Her strategic insights into global market access, reimbursement, and commercial scaling will guide Dxcover through its go-to-market strategy and CLIA rollout. Chick previously led area sales, operations, analytics, and market access teams at Sanofi.
Preparing for Growth
With these appointments, Dxcover is well-positioned to expand access to its platform, broaden its diagnostic menu into additional cancer types, pursue regulatory milestones, and deliver its technology into the hands of physicians and their patients globally. The deep clinical insight and strategic expertise of these new members will be instrumental in achieving these goals.
Marc Jones, the Chief Executive Officer of Altoida, has over 25 years of experience in health technology, diagnostics, software, and AI-powered platforms. At Altoida, he leads the development of digital biomarkers for neurological diseases using artificial intelligence and real-world data. Jones's experience will undoubtedly contribute to Dxcover's growth and success.
[1] Source: Dxcover press release, [Date]
Read also:
- Analysis of Ro Hair Loss Solution: Is it the Optimal Choice for Male Pattern Baldness?
- Is it possible that engaging in reading practices can help ward off Dementia?
- Breast-related Hidradenitis Suppurativa: Information on Prevention, Treatment, and Additional Details
- Sputnik V vaccine's five-yearmark: Russian expertise proves vital in combating the pandemic's toughest phases
